S John Weroha

List of Publications by Year
in descending order

47 papers	3,062 citations	304743 22 h-index	243625 44 g-index
47 all docs	47 docs citations	47 times ranked	5583 citing authors

#	Article	IF	Citations
1	Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer. Cancer Research, 2022, 82, 1038-1054.	0.9	26
2	Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma. Cancer Research, 2022, 82, 307-319.	0.9	8
3	Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: A case report and review of the literature. Gynecologic Oncology Reports, 2022, 39, 100923.	0.6	6
4	High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas. Gynecologic Oncology Reports, 2022, 41, 100987.	0.6	3
5	Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors. Translational Oncology, 2022, 21, 101427.	3.7	1
6	GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma. Cancer Research, 2021, 81, 2995-3007.	0.9	15
7	Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments. Cancer Research, 2021, 81, 3727-3737.	0.9	20
8	Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. Scientific Reports, 2021, 11, 8076.	3.3	9
9	Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing. BMC Medical Genomics, 2021, 14, 165.	1.5	10
10	Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer, 2021, 3, zcab028.	3.1	20
11	Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. Cancer Research, 2021, 81, 4709-4722.	0.9	42
12	Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options. PLoS ONE, 2021, 16, e0245664.	2.5	5
13	CHFR and Paclitaxel Sensitivity of Ovarian Cancer. Cancers, 2021, 13, 6043.	3.7	0
14	Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Reports Medicine, 2021, 2, 100471.	6.5	26
15	Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagyâ€mediated drug resistance in ovarian cancer cells, xenografts, and patientâ€derived xenograft models. Cancer, 2020, 126, 894-907.	4.1	54
16	Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. Nature Communications, 2020, 11, 5173.	12.8	46
17	A microfluidic platform for cultivating ovarian cancer spheroids and testing their responses to chemotherapies. Microsystems and Nanoengineering, 2020, 6, 93.	7.0	56
18	Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. ESMO Open, 2020, 5, e000926.	4.5	35

#	Article	IF	Citations
19	Targeting an autocrine IL-6â€“SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma. Oncogene, 2020, 39, 6606-6618.	5.9	15
20	Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer. Theranostics, 2020, 10, 2095-2114.	10.0	15
21	The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer. Clinical Cancer Research, 2020, 26, 3397-3407.	7.0	45
22	Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma. Cancers, 2020, 12, 869.	3.7	7
23	Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer. Scientific Reports, 2019, 9, 11153.	3.3	44
24	BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents. Cancer Research, 2019, 79, 5920-5929.	0.9	40
25	ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer. Nature Communications, 2019, 10, 4632.	12.8	21
26	Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts. Scientific Reports, 2019, 9, 6314.	3.3	33
27	Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A. PLoS ONE, 2019, 14, e0224564.	2.5	6
28	Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. Journal of the National Cancer Institute, 2018, 110, 1123-1132.	6.3	83
29	Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1101-1109.	2.5	26
30	Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With Cancer. American Journal of Hospice and Palliative Medicine, 2018, 35, 1384-1389.	1.4	0
31	LY2157299 Monohydrate, a TGF-Î²R1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer. Cancers, 2018, 10, 260.	3.7	42
32	Senolytics improve physical function and increase lifespan in old age. Nature Medicine, 2018, 24, 1246-1256.	30.7	1,384
33	Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. Gynecologic Oncology, 2017, 146, 64-68.	1.4	35
34	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Research, 2017, 77, e62-e66.	0.9	92
35	Loss of FOXO1 Cooperates with TMPRSS2â€“ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion. Cancer Research, 2017, 77, 6524-6537.	0.9	51
36	LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. Cancer Cell, 2017, 32, 310-323.e5.	16.8	80

#	Article	IF	Citations
37	Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts. Neoplasia, 2017, 19, 628-636.	5.3	49
38	Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes. Oncotarget, 2017, 8, 46891-46899.	1.8	22
39	Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR. Oncotarget, 2017, 8, 85214-85223.	1.8	6
40	Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer. BMC Cancer, 2016, 16, 814.	2.6	8
41	Ureteral obstruction in cancer patients: a qualitative study. Psycho-Oncology, 2016, 25, 605-609.	2.3	3
42	In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecologic Oncology, 2016, 143, 379-388.	1.4	57
43	Conventional Chemotherapy and Oncogenic Pathway Targeting in Ovarian Carcinosarcoma Using a Patient-Derived Tumorgraft. PLoS ONE, 2015, 10, e0126867.	2.5	24
44	Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer. Clinical Cancer Research, 2014, 20, 1288-1297.	7.0	168
45	The Insulin-Like Growth Factor System in Cancer. Endocrinology and Metabolism Clinics of North America, 2012, 41, 335-350.	3.2	165
46	Letter to the editor. Medical Oncology, 2010, 27, 569-569.	2.5	0
47	IGF-1 Receptor Inhibitors in Clinical Trialsâ€"Early Lessons. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 471-483.	2.7	159